Prognostic evaluation of Interleukin 17A and Myeloid Derived Suppressor Cells in Colorectal cancer patients.

IBRAHIM A. ALTEMEMI, OSAMAH ABD ALI NASSR

Abstract


The current study was focused on patients with Colorectal Cancer between the ages of (26–82years). The objective of this study to determine the IL-17 level and CD33 expression status in patients with Colorectal Cancer. A total 60 of (40 patients and 20 control groups) were collected from Gastroenterology and Liver diseases teaching hospital from March 2018 to the end of May 2018 Iraq. The results show Median IL-17 was significantly higher in study group than in control group (p less than 0.001), 12.13 (9.73) pg/ml versus 0.41 (0.67) pg/ml, and Median CD33 was significantly higher in study group than in control group (p less than 0.001), 73.00 (5.0) % versus 4.50 (3.75) %.

Keywords


Colorectal Cancer, IL 17, CD33.

Full Text:

PDF


DOI: https://doi.org/10.25258/ijddt.v9i3.14

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.